Endocrine Abstracts

BackgroundIn postmenopausal women, rapidly progressive hirsuitism or virilization raises the suspicion of an androgen-secreting tumor. Adrenal tumours are usually ruled out by hormonal testing and imaging studies. Small virilizing ovarian tumours may not be detectable by imaging studies.CaseA 61-year-old woman presented with hirsutism and male-pattern baldness developing over a two year period. 40 years previ...

HHS is a rare hyperglycaemic emergency, typically precipitated by infection in people with T2DM. There are few recorded cases of COVID induced pure HHS. We here by report 2 further cases, including the first known reported case in a person with T1DM.Case 1: 81yo male with T1DM (on glargine and aspart insulin, HbA1c 57 mmol/mol) presentedwith lethargy, general deterioration and a fall.Therewere no new symptoms offever/cough/breathlessness or change in tas...

Cabergoline is a dopamine agonist that may be used as primary or adjunctive therapy for acromegaly. Although one study suggested biochemical control may be achieved in a substantial proportion of patients (Abs et al, JCEM 1998), it is still commonly perceived to be a relatively ineffective treatment, possibly on account of inadequate dosing.We performed a retrospective case notes review of 9 consecutive acromegalic patients to determine the effectiveness...

BackgroundThe role of endocrine testing in idiopathic gynecomastia is controversial. Previous studies suggested that such testing is rarely productive and best done selectively.ObjectivesA retrospective study was performed to evaluate the usefulness of a routine endocrine testing in patients presenting with gynecomastia.MethodsThe medical records of 71 patients wi...

Exercise is a potent stimulus for growth hormone (GH) release and a single 30 s sprint elicits a marked increase in circulating GH. However, the mechanisms regulating GH release during and after exercise are not fully understood (1). The aim of the present study was to determine whether age, body composition, the metabolic response to or performance during a single 30 s sprint are predictors of the GH response in young men.Following local Ethics Committe...

Glycogen storage disease 1A (GSD1A) is an inherited metabolic disorder caused by glucose-6-phosphatase (G6PC) deficiency. Patients with GSD1A present disturbed glucose homeostasis and exhibit glycogen accumulation accompanied by hepatomegaly, hypoglycemia, lactic acidosis and hyperlipidemia. However, there are currently no licensed treatments for GSD1A, and human in vitro systems for disease modelling and drug screening are lacking. We aimed to develop a human hepatoc...

Background: It is widely believed that increased circulatory concentrations of long-chain saturated fatty acids (LC-SFA) significantly contribute to the death and dysfunction of pancreatic β-cells in the development of type 2 diabetes (T2D). The mechanism by which LC-SFA cross the β-cell plasma membrane has not been fully established. This work aims to characterise the mechanism underpinning this uptake. Ultimately, regulation of LC-SFA entry may maintain β-cell...

Background: Type 1 diabetes mellitus (T1DM) is caused by destruction of pancreatic beta cells. Children and adolescents with type 1 diabetes have an increased risk of developing other autoimmune diseases, most commonly autoimmune thyroiditis and celiac disease.Objectives: To examine the frequency of individual human leukocyte antigen (HLA) alleles in people with T1DM and associated autoimmune (AI) diseases of the thyroid, digestive system, and skin, and ...

Background: We investigated the frequency of autoimmune thyroid and diabetes antibodies in patients with type 1 diabetes mellitus (T1DM), their siblings, and controls.Methods: Glutamic acid decarboxylase antibodies (GADA), islet cell antibodies (ICA), insulin autoantibodies (IAA), and thyroid antibodies were identified in all subjects.Results: The rates of positive GADA and IAA were significantly higher in probands compared to sibl...

Octreotide is first-line medical therapy for patients with acromegaly. Up to 80% of patients are not satisfactorily controlled on octreotide alone and up to 20% have no response. COR-005 (previously DG3173) is a novel somatostatin analogue under investigation for treatment of acromegaly. COR-005 has high affinity for human somatostatin receptor subtypes 2, 4 and 5.The study was designed to assess pharmacokinetics of escalating doses COR-005 sc tid and co...